Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02198508
Other study ID # DMR-096-IRB-037
Secondary ID
Status Completed
Phase N/A
First received July 19, 2014
Last updated July 22, 2014
Start date July 2007

Study information

Verified date July 2014
Source China Medical University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Three iron chelators now available on the market differ in toxicity and organ specificity; evidence on standardized chelation protocol remains inconclusive, but patients with transfusion-dependent beta-thalassemia treated with DFO infusion show significant differences in the limitations of daily activities, physical activity, and quality of life when treated with oral chelator. With licensing of DFP in America, it is reasonable to combine DFP with DFX. Patients find two oral chelators more acceptable than one oral and one injectable. This pilot study rates use of DFP for improving iron excretion profile of deferasirox.

Methods: The investigators enrolled 13 beta-thalassemia patients in China Medical University Children's Hospital in May 2009-October 2011. Five refused to take part in pharmacokinetics; they only participated in iron excretion study. Seven with irregular bowel function were unable to collect feces in the screening period as baseline data. Subjects were randomly assigned and rotated to undergo all treatments (with informed consent): (A) single oral dose of DFX 30 mg/kg once daily, (B) single oral dose of DFP 40 mg/kg twice a day, (C) oral doses of DFX and DFP administered sequentially (DFX 30 mg/kg/d, deferiprone 40 mg/kg/d and deferiprone 40 mg/kg/d at 7-hour intervals). Three-day drug dosage was followed by four-day washout. Collections of urine and stool proceeded 24 hours per day, each analyzed separately. Through a venous catheter, serial blood samples (1 mL/each sampling) were collected in glass tubes containing heparin as anticoagulant at Time 0 (pre-dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6, 7, 8, 10, 12 and 24 hours after dose; plasma concentrations of DFP and DFX were measured.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years of age or older

- serum ferritin greater than 2000 ng/mL,

- serum creatinine within normal range for a measuring laboratory

- platelet count exceeding 140000/mm3

- body weight at least 40 Kg

- None had a history of clinical significant of gastrointestinal, hepatic, renal, endocrine, oncologic, infectious, pulmonary or cardiovascular disease

Exclusion Criteria:

- HIV positive, history of immunologic hypersensitivity to any medication

- women pregnant or breast feeding

- drug or alcohol abuse

- patients showed abnormal or irregular bowel function (defined as more than three bowel movements a day or less than one bowel movement every other day)

- receiving warfarin, digoxin, or anti-arrhythmic or antiseizure medication.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DFX(Deferasirox)

DFP(Deferiprone)


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
China Medical University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary iron excretion from urine and feces by flame atomic absorption spectroscopy Collections of urine and stool (made 24 hours a day) were analyzed separately. 25-days
Secondary drug concentration in plasma by pharmacokinetics analysis Through a venous catheter, serial blood samples (1 mL/each sampling) were collected into glass tubes containing heparin as an anticoagulant at time 0 (pre-dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6, 7, 8, 10, 12 and 24 hours after dosing. Blood samples were centrifuged, with plasma collected and frozen at -20°C until analysis. 25-day
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00999349 - Therapeutic Effects of Silymarin in Patients With B-thalassemia Major Phase 2/Phase 3
Completed NCT02151526 - A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease Phase 1/Phase 2
Recruiting NCT02342145 - Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Phase 4
Completed NCT00171301 - Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Phase 4
Not yet recruiting NCT01511848 - Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload Phase 2/Phase 3
Recruiting NCT03653338 - T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias Phase 1/Phase 2
Recruiting NCT06291961 - A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major Phase 1